Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is ...

Spironolactone is a diuretic (water pill) commonly used to treat heart failure and high blood pressure, but it can also be ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

Learn how failing kidneys cause dangerous fluid buildup, blood cell reduction, heart-threatening electrolyte imbalances, and ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Acute kidney injury (AKI) and vitamin D deficiency have a bi-directional relationship. Patients with sepsis AKI might be helped by vitamin D supplementation.

HALF a million Brits with deadly high blood pressure could be cured by a transformative new treatment. Doctors from the UK ...